Post-operative Radiotherapy in Poor Responders Ewing's Sarcoma Patients
- Conditions
- Ewing's Sarcoma
- Interventions
- Radiation: External Beam Radiotherapy
- Registration Number
- NCT01734863
- Lead Sponsor
- Children's Cancer Hospital Egypt 57357
- Brief Summary
Local recurrence after surgical resection is a complex phenomenon. An important predictive factor is the response to chemotherapy. Central site of disease may be a second independent predictive factor (Lin et al. 2007). Patients with more than 10% viable tumour cells at surgery following neo-adjuvant chemotherapy had a less favourable outcome with an Event-free Survival \[EFS\] of 47% after 10 years. Patients with good histological response (\< 10% viable tumour cells) after chemotherapy alone had a prognosis of about 70% after 10 years.
However, further studies are necessary to determine the merit of adjuvant radiation for high-risk patients (poor responders). Taking into consideration that the toxicity and morbidity of combined surgery and radiation is greater than either alone and must be closely monitored.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- All
- Target Recruitment
- Not specified
- Age < 18 years old.
- Non-metastatic Ewing Sarcoma patients who will undergo surgery and show poor histologic response to neo-adjuvant chemotherapy.
- Negative surgical margins.
- Patients show good safety profile and acceptable performance status.
- Patients who show progressive disease and undergo surgery before the time of local control.
- Patients who undergo Amputation or Rotationplasty will be excluded.
- Post-surgical complications that may hinder the administration of radiotherapy
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Radiotherapy Arm External Beam Radiotherapy this study arm will take External Beam radiotherapy as follows : * Radiotherapy Technique: Conformal radiotherapy, Intensity modulated radiotherapy \[IMRT\] is allowed. * Radiotherapy Dose: 45 Gy/25 fractions/5 weeks (1.8 Gy/fraction). , the inclusion criteria are as following: 1. Age \< 18 years old. 2. Non-metastatic Ewing Sarcoma patients who will undergo surgery and show poor histologic response to neo-adjuvant chemotherapy. 3. Negative surgical margins. 4. Patients show good safety profile and acceptable performance status.
- Primary Outcome Measures
Name Time Method improved Local Relapse-free Survival (LRFS) five year event free survival Determine whether the administration of post-operative radiotherapy for poor responder Ewing Sarcoma patients to neo-adjuvant chemotherapy and radical surgery, leads to improved Local Relapse-free Survival (LRFS).
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Children's Cancer Hospital Egypt 57357
🇪🇬Cairo, Egypt